Frequently Asked Questions

No. LiZhiZhu Compound Calcium Carbonate Granules from Wuhan Ximo is approval H20173214. Effervescent granules under H20040896 are a different product from another manufacturer. H20070183 is a historical discontinued approval. Their labels and approval identifiers must not be mixed.

LiZhiZhu is a calcium supplement brand of Wuhan Ximo Pharmaceutical Co., Ltd. Its generic name is Compound Calcium Carbonate Granules, with China Drug Approval Number H20173214. It is a prescription drug in granule form.

Each 3.4 g sachet contains 0.75 g of calcium carbonate (about 0.3 g elemental calcium) and 62.5 IU of vitamin D3.

Each sachet contains calcium carbonate 0.75 g and vitamin D3 62.5 IU. Formulation research concerns complexation and inclusion technologies. Ingredient differences alone do not establish greater efficacy for every person; clinical assessment should guide selection.

Each 3.4 g sachet provides 0.75 g calcium carbonate (about 0.3 g elemental calcium) plus 62.5 IU vitamin D3.

The label recommends 500-1000 mg of calcium per day: adults 1 sachet 2-3 times daily; children 1 sachet 1-2 times daily, or as directed by a physician.

According to the current label, it is indicated for the prevention and treatment of calcium deficiency, including osteoporosis, tetany, osteodysplasia, rickets, and calcium supplementation for pregnant, lactating and menopausal women.

The current label explicitly includes calcium supplementation for pregnant and lactating women among its indications.

The Chinese Expert Consensus on Calcium Supplementation for Pregnant and Lactating Women (2021) provides professional guidance.

Dosage should follow medical advice and be adjusted according to dietary calcium intake.

Calcium supplementation for menopausal women is explicitly listed among the approved indications.

Declining estrogen after menopause affects bone metabolism and accelerates calcium loss, making this group prone to osteoporosis.

A supplementation plan should be based on bone density testing and physician guidance.

Do not use this medicine during digitalis treatment. If you take other medicines, give your physician or pharmacist a complete medication list to check whether combined use is appropriate and whether administration times need adjustment.

Use about 50–60 mL of cooled boiled water as stated in the label, and take promptly after bubbling subsides in about 5–8 minutes. Do not independently substitute milk. The label mentions milk-alkali syndrome; dietary dairy intake and preparation of medicine are different questions. Consult a professional about combined calcium and vitamin D intake.

Per the label: pour one sachet into a cup, add about 50-60 mL of cool boiled water, wait 5-8 minutes until effervescence stops, then take orally immediately.

Dosage: 500-1000 mg calcium daily; adults 1 sachet 2-3 times daily; children 1 sachet 1-2 times daily, or as directed by a physician.

According to the current label, contraindications include: hypersensitivity to any component; hypercalcemia, hypercalciuria, hypervitaminosis D, and renal rickets with hyperphosphatemia; and concurrent use of digitalis preparations.

Per the current label, possible adverse reactions include: belching and constipation; rarely, milk-alkali syndrome presenting as hypercalcemia, alkalosis and renal impairment.

Precautions: use with caution in patients with renal impairment, arteriosclerosis, cardiac insufficiency, hypercholesterolemia, hyperphosphatemia, or vitamin D allergy. Do not use if the product appearance changes. Keep out of reach of children. Consult a physician or pharmacist if taking other medications.

The project “Key technology innovation and industrialisation of compound calcium carbonate granules” received the 2021 Hubei Science and Technology Progress Award, Second Prize, with Wuhan Ximo listed among the completing organisations. LiZhiZhu also received the 2018 Golden Brick Product industry honour. See About Us for the award information and records.

LiZhiZhu applies two core technologies: complexation technology to improve calcium dissolution and absorption, and vitamin D3 inclusion technology to improve stability.

Note: referenced studies include cell and animal experiments, whose conclusions cannot be directly equated with absolute human efficacy.